Using nonfasting lipids - Hemodilution or convenience?

Clinical Chemistry

Volumn 57, Issue 9, 2011, Pages 1336-1338

  Lund, Søren S ^a   Jensen, Tonny ^a,b  

^a STENO DIABETES CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AGE; ALBUMIN BLOOD LEVEL; ANALYTICAL ERROR; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DIET RESTRICTION; FLUID INTAKE; FOOD INTAKE; HEALTH CARE QUALITY; HEMOCONCENTRATION; HEMODILUTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; LETTER; LIPID ANALYSIS; LIVER METABOLISM; PATIENT SELECTION; POSTPRANDIAL STATE; PROTEIN METABOLISM; RISK REDUCTION; SAMPLE SIZE; SEX; SMOKING; THROMBOCYTE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

BLOOD CHEMICAL ANALYSIS; DIABETES MELLITUS; FASTING; FEMALE; HUMANS; LIPIDS; MALE; POPULATION SURVEILLANCE;

EID: 80052233647     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2011.168104     Document Type: Letter

References (13)

1. Langsted A, Nordestgaard BG. Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen General Population Study. Clin Chem 2011;57:482-9.
2. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 2008;118:2047-56.
3. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990;1:43-6.
4. Rahilly-Tierney CR, Lawler EV, Scranton RE, Gaziano JM. Cardiovascular benefit of magnitude of low-density lipoprotein cholesterol reduction: a comparison of subgroups by age. Circulation 2009;120:1491-7.
5. Howard BV, Robbins DC, Sievers ML, Lee ET, Rhoades D, Devereux RB, et al. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study. Arterioscler Thromb Vasc Biol 2000;20:830-5.
6. Linsel-Nitschke P, Götz A, Erdmann J, Braenne I, Braund P, Hengstenberg C, et al. Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease - a Mendelian randomisation study. PLoS One 2008;3:e2986.
7. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81.
8. Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 2008;118:993-1001.
9. Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000.
10. Thompson A, Danesh J. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med 2006;259:481-92.
11. Lund SS, Petersen M, Frandsen M, Smidt UM, Parving HH, Vaag AA, Jensen T. Agreement between fasting and postprandial LDL cholesterol measured with 3 methods in patients with type 2 diabetes mellitus. Clin Chem 2011;57:298-308.
12. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
13. Watts GF, Cohn JS. Whither the lipid profile: feast, famine, or no free lunch? Clin Chem 2011;57:363-5.